Drug Trial Radar · NCT04945460
A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)
Last checked: Nov 20, 2026Latest source record: Sep 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
165
Actual
Start
Dec 29, 2021
Primary completion
Sep 5, 2025
Study completion Apr 9, 2026
Sponsor
- Lead sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USAIndustry
- Sponsor type
- Industry
- First posted
- Jun 30, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2, double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of sotatercept versus placebo in adults with Cpc-PH due to HFpEF. The objective of this study is to evaluate the efficacy, safety and tolerability of sotatercept versus placebo in adults with Cpc-PH due to HFpEF. Efficacy is measured by change from baseline in pulmonary vascular resistance (PVR, primary endpoint) and 6-minute walk distance (6MWD, key secondary endpoint).
Conditions
- Hypertension, Pulmonary
Interventions
Sotatercept 0.3 mg/kgDrug
Administered by subcutaneous injection. Sotatercept (ACE-011) is a recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA linked to the Fc piece of human IgG1.
PlaceboDrug
Administered by subcutaneous injection
Sotatercept 0.3 mg/kg escalating to 0.7 mg/kgDrug
Administered by subcutaneous injection. Sotatercept (ACE-011) is a recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA linked to the Fc piece of human IgG1.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Base Study: Change From Baseline in Pulmonary Vascular Resistance (PVR) at Week 24Time frame: Baseline and Week 24
Locations
119 sites in 12 countries. Site status is shown where the registry gives one.
PULMONARY ASSOCIATES, P.A. ( Site 1008)
Phoenix, Arizona
University of Arizona ( Site 1006)
Tucson, Arizona
Scripps Clinic ( Site 4001)
La Jolla, California
Cedars Sinai Medical Center ( Site 1082)
Los Angeles, California
University of California Irvine ( Site 1086)
Orange, California
Jeffrey S.Sager MD Medical Corporation ( Site 1060)
Santa Barbara, California
Stanford University ( Site 1024)
Stanford, California
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center ( Site 1028)
Torrance, California
University Of Colorado ( Site 1013)
Aurora, Colorado
South Denver Cardiology Associates ( Site 1091)
Littleton, Colorado
Winchester Chest Clinic ( Site 1093)
New Haven, Connecticut
The George Washington University Medical Faculty Associates ( Site 1025)
Washington D.C., District of Columbia
Bay Area Cardiology ( Site 1071)
Brandon, Florida
Mayo Clinic Jacksonville - PPDS ( Site 1045)
Jacksonville, Florida
AdventHealth Orlando ( Site 1058)
Orlando, Florida
Tampa General Hospital ( Site 1043)
Tampa, Florida
Piedmont Atlanta Hospital ( Site 1085)
Atlanta, Georgia
Emory University ( Site 1030)
Atlanta, Georgia
Saint Alphonsus Regional Medical Center ( Site 1097)
Boise, Idaho
University of Illinois Hospital ( Site 1095)
Chicago, Illinois
IU Health Advanced Heart and Lung Care ( Site 1092)
Indianapolis, Indiana
Ascension Medical Group St. Vincent ( Site 1076)
Indianapolis, Indiana
University of Iowa Hospital and Clinics ( Site 1050)
Iowa City, Iowa
University of Kansas Medical Center ( Site 1020)
Kansas City, Kansas
Norton Pulmonary Specialists ( Site 1066)
Louisville, Kentucky
University of Louisville ( Site 1099)
Louisville, Kentucky
University Medical Center New Orleans ( Site 1057)
New Orleans, Louisiana
Tufts Medical Center - PPDS ( Site 1012)
Boston, Massachusetts
Brigham and Women's Hospital [Boston, MA] ( Site 1014)
Boston, Massachusetts
University of Michigan ( Site 1011)
Ann Arbor, Michigan
University of Minnesota Hospitals ( Site 1062)
Minneapolis, Minnesota
Washington University School of Medicine [Saint Louis, MO] ( Site 1022)
St Louis, Missouri
University of Nebraska Medical Center ( Site 1053)
Omaha, Nebraska
Pulmonary Health Physicians ( Site 1080)
Liverpool, New York
Weill Cornell Medical College ( Site 1046)
New York, New York
University of Rochester Medical Center - PPDS ( Site 1039)
Rochester, New York
Duke University Medical Center ( Site 1026)
Durham, North Carolina
The Carl and Edyth Lindner Center for Research and Education at the Christ Hospital ( Site 1001)
Cincinnati, Ohio
University Hospitals Cleveland Medical Center ( Site 1005)
Cleveland, Ohio
Cleveland Clinic Foundation ( Site 1065)
Cleveland, Ohio
Showing 40 of 119 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.